SNN vs BIO
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 12, 2026
SNN
BIO
Investment Advisor Scores
BIO
AI Analyst Insights
Detailed Metrics Comparison
| Metric | SNN | BIO | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 11.1857 | 40.6504 | SNN |
| PEG Ratio | 1.0712 | 1.1905 | SNN |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 4.6% | 0.5% | SNN |
| Earnings Growth | 5.7% | 18.7% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 39.7/100 | 59.5/100 | BIO |
| Profit Margin | 10.1% | 39.5% | BIO |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | BUY | BIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
SNN
MarkupPrice above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
BIO
DistributionPrice near a flattening SMA50 (slope 0.2%) with fading momentum, RSI 48
Fundamentals Snapshot
| Metric | SNN | BIO |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.1 | 39.0 |
| Trailing P/E | 21.0 | 10.3 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.7% | 0.5% |
| Operating Margin | 0.1% | 0.1% |
| EPS | 1.47 | 37.64 |
| Dividend Yield | 0.03% | — |